JP2004509941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509941A5 JP2004509941A5 JP2002531082A JP2002531082A JP2004509941A5 JP 2004509941 A5 JP2004509941 A5 JP 2004509941A5 JP 2002531082 A JP2002531082 A JP 2002531082A JP 2002531082 A JP2002531082 A JP 2002531082A JP 2004509941 A5 JP2004509941 A5 JP 2004509941A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- group
- leader group
- alkylene
- acid leader
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 101
- -1 chloro, bromo, iodo, methyl Chemical group 0.000 description 59
- 239000002253 acid Substances 0.000 description 37
- 125000002947 alkylene group Chemical group 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 125000001153 fluoro group Chemical group F* 0.000 description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 16
- 150000001408 amides Chemical group 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 15
- 125000000732 arylene group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 9
- 150000002170 ethers Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- MHJROHFILMZTFC-UHFFFAOYSA-N CCN(CC)NN1CCOC(C1)(N)N(C)C Chemical compound CCN(CC)NN1CCOC(C1)(N)N(C)C MHJROHFILMZTFC-UHFFFAOYSA-N 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000015336 Helminthic disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- ABDMQSFNJPYOLA-UHFFFAOYSA-N NS(=O)(=O)[N+]([O-])=O Chemical compound NS(=O)(=O)[N+]([O-])=O ABDMQSFNJPYOLA-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005488 carboaryl group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical group OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023985A GB0023985D0 (en) | 2000-09-29 | 2000-09-29 | Therapeutic compounds |
| US29778501P | 2001-06-14 | 2001-06-14 | |
| PCT/GB2001/004329 WO2002026696A1 (en) | 2000-09-29 | 2001-09-27 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004509941A JP2004509941A (ja) | 2004-04-02 |
| JP2004509941A5 true JP2004509941A5 (enExample) | 2008-10-23 |
Family
ID=26245083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002531082A Pending JP2004509941A (ja) | 2000-09-29 | 2001-09-27 | Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7569724B2 (enExample) |
| EP (3) | EP1598067B1 (enExample) |
| JP (1) | JP2004509941A (enExample) |
| AT (2) | ATE310719T1 (enExample) |
| AU (1) | AU2001290134A1 (enExample) |
| CA (1) | CA2423868C (enExample) |
| DE (2) | DE60138658D1 (enExample) |
| DK (1) | DK1335898T3 (enExample) |
| ES (1) | ES2257441T3 (enExample) |
| WO (1) | WO2002026696A1 (enExample) |
Families Citing this family (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| US20030129724A1 (en) * | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| EP1443928B1 (en) | 2001-10-16 | 2011-07-27 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| DE60216972T2 (de) * | 2001-12-04 | 2007-10-18 | De Novo Pharmaceuticals Ltd., Histon | Bakterielle enzyminhibitoren |
| NZ536116A (en) | 2002-04-03 | 2007-01-26 | Topotarget Uk Ltd | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors |
| KR20050034732A (ko) * | 2002-08-02 | 2005-04-14 | 아젠터 디스커버리 리미티드 | 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산 |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP4612621B2 (ja) | 2003-01-17 | 2011-01-12 | トポターゲット ユーケー リミテッド | Ｈｄａｃ阻害剤としてのエステル又はケトン結合を含むカルバミン酸化合物 |
| AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| EP1599449A2 (en) | 2003-02-25 | 2005-11-30 | TopoTarget UK Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7842835B2 (en) | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| EP1644323B1 (en) * | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| JP4799408B2 (ja) * | 2003-07-15 | 2011-10-26 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 新規な２−オキソ複素環化合物およびそれを含有する薬剤組成物の使用 |
| WO2005014588A1 (en) * | 2003-08-01 | 2005-02-17 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids having histone deacetylase activity |
| MXPA05011286A (es) | 2003-08-20 | 2006-01-24 | Axys Pharm Inc | Derivados de acetileno como inhibidores de histona deacetilasa. |
| KR101127201B1 (ko) * | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| CA2552279C (en) | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| GB0402380D0 (en) * | 2004-02-03 | 2004-03-10 | Argenta Discovery Ltd | Novel compounds |
| ITMI20041347A1 (it) | 2004-07-05 | 2004-10-05 | Italfarmaco Spa | Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1781289A1 (en) | 2004-07-22 | 2007-05-09 | PTC Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| KR100620488B1 (ko) | 2004-08-13 | 2006-09-08 | 연세대학교 산학협력단 | 신규한 히스톤 디아세틸라아제 억제제 및 이의 제조방법 |
| US7202383B2 (en) | 2004-09-14 | 2007-04-10 | The Hospital For Sick Children | Compounds useful for modulating abnormal cell proliferation |
| ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
| US8242175B2 (en) | 2004-10-01 | 2012-08-14 | Dac S.R.L. | Class of histone deacetylase inhibitors |
| EP1812451A4 (en) * | 2004-11-01 | 2009-10-21 | Nuada Llc | COMPOUNDS AND METHODS OF USE THEREOF |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| SG171690A1 (en) * | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| CN101180288A (zh) * | 2005-03-31 | 2008-05-14 | 科学与工业研究会 | 与抗感染药物联用的芳香族取代的戊二烯酸酰胺 |
| KR100844277B1 (ko) * | 2005-04-29 | 2008-07-07 | (주)아모레퍼시픽 | 히드록삼산 유도체 및 이의 제조방법 |
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| SI1901729T1 (sl) | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| CA2615105A1 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| EP1975158B9 (en) * | 2005-12-27 | 2012-02-29 | Universidad Del Pais Vasco-Euskal Herriko Unibersitatea | Novel pyrrole derivatives with histone deacetylase inhibitor activity |
| WO2008091349A1 (en) * | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
| DK2010168T3 (da) | 2006-02-14 | 2014-07-21 | Harvard College | Histondeacetylase-inhibitore |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007113644A2 (en) * | 2006-04-05 | 2007-10-11 | Orchid Research Laboratories Limited | New hdac inhibitors |
| WO2007130429A2 (en) * | 2006-05-03 | 2007-11-15 | The President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2659478A1 (en) * | 2006-08-03 | 2008-02-14 | Georgetown University | Isoform-selective hdac inhibitors |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CA2668070A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| US20100256147A1 (en) * | 2007-04-13 | 2010-10-07 | Hangauer Jr David G | Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders |
| CA2691987C (en) * | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| WO2009009041A2 (en) * | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
| JP2010536876A (ja) * | 2007-08-21 | 2010-12-02 | アークル インコーポレイテッド | Ｈｄａｃインヒビター |
| CN101868446A (zh) | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| CA2702536A1 (en) * | 2007-10-10 | 2009-04-16 | Orchid Research Laboratories Limited | Novel histone deacetylase inhibitors |
| US8293513B2 (en) * | 2007-12-14 | 2012-10-23 | Georgetown University | Histone deacetylase inhibitors |
| US7863315B2 (en) | 2008-01-15 | 2011-01-04 | Shenzhen Chipscreen Biosciences, Ltd. | 2-indolinone derivatives as selective histone deacetylase inhibitors |
| SI2262493T1 (sl) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata |
| US8158656B2 (en) | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
| US8178577B2 (en) | 2008-05-21 | 2012-05-15 | Shenzhen Chipscreen Biosciences Ltd. | Tricyclic derivatives as potent and selective histone deacetylase inhibitors |
| EP2321264B1 (en) * | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| ME02254B (me) | 2009-01-23 | 2015-12-31 | Euro Celtique Sa | Derivati hidroksamske kiseline |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| GB0903480D0 (en) * | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
| PL2435409T3 (pl) | 2009-05-28 | 2015-01-30 | Novartis Ag | Podstawione pochodne aminopropionowe jako inhibitory neprylizyny |
| CA2763565A1 (en) | 2009-05-28 | 2010-12-02 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
| EP2440053A4 (en) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
| WO2010144586A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| CA2765030C (en) | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| CN102020588B (zh) * | 2009-09-16 | 2014-01-29 | 深圳微芯生物科技有限责任公司 | 具有组蛋白去乙酰化酶抑制活性的三环化合物、其制备方法及应用 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| TWI429628B (zh) | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
| EP2571352A4 (en) * | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
| CN102775368B (zh) * | 2011-05-10 | 2016-08-17 | 上海驺虞医药科技有限公司 | 一类噻唑类化合物及其制备方法和用途 |
| EP2548869A1 (en) * | 2011-07-20 | 2013-01-23 | Cytec Technology Corp. | Process for the Synthesis of N-substituted Cyclic Alkylene Ureas |
| AR087342A1 (es) | 2011-07-29 | 2014-03-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y sus usos |
| EA201490406A1 (ru) * | 2011-07-29 | 2014-07-30 | Кариофарм Терапевтикс, Инк. | Модуляторы ядерного транспорта и их применение |
| WO2013052110A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| SMT202000347T1 (it) * | 2012-05-09 | 2020-07-08 | Biogen Ma Inc | Modulatori di trasporto nucleare e loro usi |
| WO2013170165A1 (en) | 2012-05-10 | 2013-11-14 | Achaogen, Inc. | Antibacterial agents |
| WO2014011713A2 (en) | 2012-07-10 | 2014-01-16 | Dana-Farber Cancer Institue, Inc. | Anti-proliferative compounds and uses thereof |
| US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
| WO2014126972A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
| SG11201506018PA (en) | 2013-02-14 | 2015-08-28 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| KR102322794B1 (ko) | 2013-06-21 | 2021-11-05 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 핵수송 조절인자 및 이의 용도 |
| WO2015051035A1 (en) | 2013-10-01 | 2015-04-09 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
| EP3062783B1 (en) | 2013-10-18 | 2020-08-12 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
| CA2933907A1 (en) | 2013-12-23 | 2015-07-02 | The Trustees Of Columbia University In The City Of New York | Selective hdac6 inhibitors |
| KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
| MA39171A1 (fr) | 2014-01-10 | 2017-07-31 | Glaxosmithkline Intellectual Property (No 2) Ltd | Dérivés d'hydroxy formamide et leur utilisation |
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| SG11201700789SA (en) | 2014-08-15 | 2017-02-27 | Karyopharm Therapeutics Inc | Polymorphs of selinexor |
| US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| US9809539B2 (en) | 2015-03-03 | 2017-11-07 | Shuttle Pharmaceuticals, Llc | Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof |
| US9745253B2 (en) | 2015-03-13 | 2017-08-29 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
| EP3283066B1 (en) * | 2015-04-16 | 2022-05-11 | Phenotec AG | 4-phenylbutyric acid derivatives |
| EP3307746A1 (en) * | 2015-05-18 | 2018-04-18 | National and Kapodistrian Universty of Athens | Autotaxin inhibitors and uses thereof |
| MY195058A (en) | 2015-05-22 | 2023-01-05 | Chong Kun Dang Pharmaceutical Corp | Heterocyclicalkyl Derivative Compounds as Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising the Same |
| EP4006012A1 (en) | 2015-10-15 | 2022-06-01 | Cornell University | Proteasome inhibitors and uses thereof |
| US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| WO2019075252A1 (en) | 2017-10-11 | 2019-04-18 | Cornell University | PEPTIDOMIMETIC INHIBITORS OF PROTEASOME |
| WO2019102488A1 (en) | 2017-11-27 | 2019-05-31 | Council Of Scientific & Industrial Research | Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors |
| WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| EP3897626B1 (en) | 2018-12-18 | 2025-09-10 | Mundipharma International Corporation Limited | Tinostamustine for treating multiple myeloma |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112592305B (zh) * | 2020-12-23 | 2022-10-18 | 中南大学 | 一种有机化合物及其制备方法和应用 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| EP4337653A4 (en) * | 2021-06-02 | 2025-07-23 | Univ North Carolina Chapel Hill | RNA TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME |
| EP4370109A4 (en) * | 2021-07-14 | 2025-10-22 | Univ Maryland | SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES AND NANOPARTICLES, AND METHODS OF USE THEREOF |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| US20250213523A1 (en) | 2022-04-05 | 2025-07-03 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| WO2025026925A1 (en) | 2023-07-28 | 2025-02-06 | Ospedale San Raffaele S.R.L. | Gtf2i inhibitors and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1571198A (enExample) | 1967-06-28 | 1969-06-13 | ||
| CA1317962C (en) | 1987-07-29 | 1993-05-18 | Naoto Hashimoto | Cell proliferation inhibitors |
| US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| DE69221290T2 (de) | 1991-12-10 | 1998-01-15 | Shionogi & Co | Auf aromatischen sulfonamiden basierende hydroxamsäurederivate |
| GB9223904D0 (en) | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
| DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
| JPH0775593A (ja) * | 1993-09-08 | 1995-03-20 | Suntory Ltd | 蛋白質の製造方法 |
| US5804601A (en) * | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| GB2312674A (en) | 1996-05-02 | 1997-11-05 | Ciba Geigy Ag | Tetrahydroquinoline inhibitors of trypsin and thrombin |
| US6001329A (en) | 1996-05-06 | 1999-12-14 | Uab Research Foundation | Radiolabeled fusion toxins for cancer therapy |
| IT1283637B1 (it) * | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| WO1998015525A1 (en) * | 1996-10-07 | 1998-04-16 | Sumitomo Pharmaceuticals Co., Ltd. | Hydroxamic acids |
| BR9714142A (pt) * | 1996-12-17 | 2000-02-29 | Warner Lambert Co | Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas |
| JPH10182583A (ja) | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | 新規ヒドロキサム酸誘導体 |
| IL131493A (en) | 1997-03-04 | 2004-05-12 | Monsanto Co | Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| WO1999005109A1 (en) | 1997-07-25 | 1999-02-04 | Tsumura & Co. | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-β INHIBITORS CONTAINING THE SAME |
| AU749132B2 (en) | 1997-08-28 | 2002-06-20 | Biovitrum Ab | Inhibitors of protein tyrosine phosphatase |
| EP1024134A4 (en) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| JPH11122671A (ja) | 1997-10-16 | 1999-04-30 | Nec Corp | 緯度経度測定機能付き無線端末システム |
| JPH11130761A (ja) | 1997-10-24 | 1999-05-18 | Otsuka Pharmaceut Co Ltd | ベンゾチアゾール誘導体 |
| WO1999024399A1 (en) | 1997-11-12 | 1999-05-20 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| PT1037868E (pt) | 1997-11-21 | 2003-06-30 | Upjohn Co | Derivados alfa-hidroxi amino e halo de acidos beta-sulfonil-hidroxamicos como inibidores de metaloproteinases matriciais |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US5986102A (en) * | 1998-04-29 | 1999-11-16 | Pharmacopeia, Inc. | Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases |
| WO2000000194A1 (en) | 1998-06-27 | 2000-01-06 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
| WO2000021979A2 (en) | 1998-10-13 | 2000-04-20 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
| AR035311A1 (es) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
| US6225311B1 (en) * | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| JP2003525203A (ja) | 1999-03-22 | 2003-08-26 | ダーウィン・ディスカバリー・リミテッド | ヒドロキサムおよびカルボン酸誘導体 |
| WO2000069819A1 (en) | 1999-05-12 | 2000-11-23 | G.D. Searle & Co. | Hydroxamic acid derivatives as matrix metalloprotease inhibitors |
| BR0014254A (pt) | 1999-09-08 | 2002-08-27 | Sloan Kettering Inst Cancer | Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos |
| US6696456B1 (en) | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
| KR20100035666A (ko) | 1999-11-23 | 2010-04-05 | 메틸진 인크. | 히스톤 디아세틸라제의 억제제 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP2292593A3 (en) | 2000-09-29 | 2011-05-25 | TopoTarget UK Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| GB0024795D0 (en) * | 2000-10-10 | 2000-11-22 | Hoffmann La Roche | Pyrazole derivatives for the treatment of viral diseases |
-
2001
- 2001-09-27 CA CA2423868A patent/CA2423868C/en not_active Expired - Fee Related
- 2001-09-27 ES ES01970014T patent/ES2257441T3/es not_active Expired - Lifetime
- 2001-09-27 DK DK01970014T patent/DK1335898T3/da active
- 2001-09-27 EP EP05015737A patent/EP1598067B1/en not_active Expired - Lifetime
- 2001-09-27 AT AT01970014T patent/ATE310719T1/de active
- 2001-09-27 WO PCT/GB2001/004329 patent/WO2002026696A1/en not_active Ceased
- 2001-09-27 EP EP09004388A patent/EP2083005A1/en not_active Withdrawn
- 2001-09-27 US US10/381,791 patent/US7569724B2/en not_active Expired - Fee Related
- 2001-09-27 DE DE60138658T patent/DE60138658D1/de not_active Expired - Fee Related
- 2001-09-27 AT AT05015737T patent/ATE430567T1/de not_active IP Right Cessation
- 2001-09-27 DE DE60115279T patent/DE60115279T2/de not_active Expired - Lifetime
- 2001-09-27 JP JP2002531082A patent/JP2004509941A/ja active Pending
- 2001-09-27 AU AU2001290134A patent/AU2001290134A1/en not_active Abandoned
- 2001-09-27 EP EP01970014A patent/EP1335898B1/en not_active Expired - Lifetime
-
2009
- 2009-06-03 US US12/477,493 patent/US7880020B2/en not_active Expired - Fee Related
-
2011
- 2011-01-04 US US12/983,971 patent/US20110105572A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2423868A1 (en) | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | |
| KR102905557B1 (ko) | THRβ 수용체 효능제 화합물 및 그의 제조 방법 및 용도 | |
| KR920006237B1 (ko) | 융합된 벤즈(티오)아미드의 제조방법 | |
| CA2565813C (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| EP1339679B1 (fr) | Derives de 3-aroylindole et leur utilisation en tant qu'agonistes des recepteurs cb2 | |
| CA2423744A1 (en) | Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | |
| AU2007225208A1 (en) | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | |
| FR2621585A1 (fr) | Derives de 4h-benzopyranne-1 one-4 et leurs sels, leurs procedes de fabrication et compositions pharmaceutiques les comprenant en tant qu'ingredients actifs | |
| JP2005529945A (ja) | オメガ−３ｐｕｆａ由来の脂質メディエーターの類似体及び使用方法 | |
| JPH0253762A (ja) | 新規スルホンアミドおよびこれを含有する、物質代謝機能病および血行障害治療薬 | |
| US6080782A (en) | Cyclohexyl dihydrobenzofuranes | |
| JP2011522847A (ja) | フッ素系界面活性剤 | |
| CN1168718C (zh) | 2-(6-取代吡啶-2-基氧甲基)苯乙酸酯的制备方法 | |
| HUT62293A (en) | Process for producing chroman derivatives and pharmaceutical compositions comprising such compounds | |
| JP2005514455A (ja) | 芳香族チオエーテル肝臓ｘ受容体モジュレータ | |
| CA2813934C (en) | Polymorphs of cddo ethyl ester and uses thereof | |
| EP1507758B1 (fr) | Derives d'indole et leur utilisation en tant que ligands des recepteurs cb2 | |
| EP2120898A1 (en) | Calcilytic compounds | |
| WO1997035835A1 (en) | 3,4-disubstituted phenylethanolaminotetralincarboxylate derivatives | |
| EP0652214A1 (fr) | Nouveaux dérivés N-aryl 2-cyano 3-hydroxy propénamides, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant | |
| JP6687477B2 (ja) | エステル化合物の製造方法 | |
| CN117843521A (zh) | 一种作为甲状腺激素β受体激动剂的化合物及其制备方法、应用 | |
| Yoshino et al. | Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists | |
| JPH02124869A (ja) | ロイコトリエン拮抗剤のエステルプロドラッグ | |
| CA2757859A1 (fr) | Derives de 1-alkyl-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique |